Cresset Asset Management LLC trimmed its holdings in shares of Centene Co. (NYSE:CNC – Free Report) by 55.2% during the fourth quarter, HoldingsChannel reports. The firm owned 956,354 shares of the company’s stock after selling 1,179,321 shares during the quarter. Cresset Asset Management LLC’s holdings in Centene were worth $57,936,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital Advisors Ltd. LLC boosted its stake in Centene by 75.3% in the fourth quarter. Capital Advisors Ltd. LLC now owns 412 shares of the company’s stock valued at $25,000 after acquiring an additional 177 shares during the last quarter. Hurley Capital LLC purchased a new position in Centene in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC bought a new position in Centene during the fourth quarter valued at $30,000. OFI Invest Asset Management purchased a new stake in Centene in the fourth quarter worth $33,000. Finally, SRS Capital Advisors Inc. raised its stake in shares of Centene by 73.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 631 shares of the company’s stock valued at $38,000 after buying an additional 267 shares during the period. 93.63% of the stock is owned by hedge funds and other institutional investors.
Centene Stock Performance
NYSE:CNC opened at $59.79 on Tuesday. Centene Co. has a twelve month low of $55.03 and a twelve month high of $80.59. The company has a quick ratio of 1.10, a current ratio of 1.11 and a debt-to-equity ratio of 0.70. The stock has a market cap of $29.75 billion, a P/E ratio of 9.58, a PEG ratio of 0.80 and a beta of 0.48. The business’s 50-day moving average price is $60.23 and its two-hundred day moving average price is $60.46.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on CNC. StockNews.com lowered Centene from a “strong-buy” rating to a “buy” rating in a report on Monday, April 28th. Argus downgraded shares of Centene from a “buy” rating to a “hold” rating in a research note on Thursday, February 6th. Jefferies Financial Group dropped their price target on shares of Centene from $64.00 to $61.00 and set a “hold” rating on the stock in a research note on Tuesday, April 29th. Wells Fargo & Company reduced their price objective on shares of Centene from $76.00 to $72.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Finally, Robert W. Baird dropped their target price on Centene from $71.00 to $69.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 15th. Seven research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $79.77.
Centene Company Profile
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.
Featured Articles
- Five stocks we like better than Centene
- Canada Bond Market Holiday: How to Invest and Trade
- Chevron’s Fundamentals Shine Through Market Turmoil
- How to Effectively Use the MarketBeat Ratings Screener
- Qualcomm: Analyst Opinions Split, But Upside Potential Remains
- Energy and Oil Stocks Explained
- Monster Beverage Stock: Short Report Risks vs Upside Potential
Want to see what other hedge funds are holding CNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centene Co. (NYSE:CNC – Free Report).
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.